<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884819</url>
  </required_header>
  <id_info>
    <org_study_id>R-08-573</org_study_id>
    <secondary_id>15581</secondary_id>
    <nct_id>NCT00884819</nct_id>
  </id_info>
  <brief_title>Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome</brief_title>
  <official_title>Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized, double-blind placebo-controlled trial of 6 months' duration
      evaluating the effect of fenofibrate (200 mg/day) in females with polycystic ovary syndrome
      and mild hypertriglyceridemia. The investigators primary objective will be to determine
      whether fenofibrate will reduce hepatic adiposity as measured using MRI, and our secondary
      outcomes will be to delineate the impact of fenofibrate on biochemical or clinical parameters
      for insulin resistance, cardiovascular disease, and reproductive status.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic adiposity as assessed using MRI</measure>
    <time_frame>6-months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition using bioelectrical impedance analysis (BIA), anthropometry (skin-fold thickness measurement), and MRI</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance using HOMA-IR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters related to insulin resistance (adipocytokines, free fatty acids, 25-hydroxyvitamin D)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional and non-traditional cardiovascular risk factors (lipids, apolipoproteins, fibrinogen, PAI-1, CRP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproductive parameters (androgens, hirsutism)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fenofibrate 200mg/daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo match for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>fenofibrate 200 mg daily for 6-months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo match for 6 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal women ≥ 18 years

          -  diagnosis of PCOS based on the recent 2006 Androgen Excess Society criteria (modified
             from Rotterdam 2003)

          -  waist circumference &gt;88 cm

          -  fasting TG 2.0 - 5.0 mmol/L

          -  stable on any type of oral contraceptive for a minimum of 3-months

        Exclusion Criteria:

          -  known contraindications for MRI

          -  pregnancy, lactation, desire to become pregnant

          -  participation in another clinical trial

          -  fasting TF level ≥ 5.0 mmol/L

          -  AST or ALT &gt; 2.5 times upper limit of normal (ULN)

          -  creatinine kinase (CK) &gt; 6x ULN

          -  creatinine &gt; 115 μmol/L

          -  fasting glucose ≥ 7.0 mmol/L and/or 2h glucose post oral glucose tolerance test (OGTT)
             ≥ 11.1 mmol/L or personal history of DM2

          -  personal history of renal disease, liver disease (except NAFLD), or heart disease

          -  body mass index (BMI) &lt; 18 or &gt; 40 kg/m²

          -  increased alcohol use (&gt;9 standard drinks per week [standard drink = 12oz beer, 5oz
             wine, or 1.5oz spirits]) or drug use

          -  use of other hormonal contraception, growth hormone, glucocorticoids,
             anti-diabetic/anti-dyslipidemia medications, or anabolic steroids.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tisha Joy, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Health Care, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Toda K, Okada T, Miyaura C, Saibara T. Fenofibrate, a ligand for PPARalpha, inhibits aromatase cytochrome P450 expression in the ovary of mouse. J Lipid Res. 2003 Feb;44(2):265-70. Epub 2002 Nov 4.</citation>
    <PMID>12576508</PMID>
  </reference>
  <reference>
    <citation>Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7.</citation>
    <PMID>15124979</PMID>
  </reference>
  <reference>
    <citation>Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun. 2002 Aug 16;296(2):293-9.</citation>
    <PMID>12163016</PMID>
  </reference>
  <reference>
    <citation>Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000 Oct;30(10):871-8.</citation>
    <PMID>11029601</PMID>
  </reference>
  <reference>
    <citation>Yong QW, Thavintharan S, Cheng A, Chew LS. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome. Ann Acad Med Singapore. 1999 Nov;28(6):778-82.</citation>
    <PMID>10672386</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Tisha Joy</investigator_full_name>
    <investigator_title>Assistant Professor, Division of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>polycystic ovary syndrome</keyword>
  <keyword>hepatic adiposity</keyword>
  <keyword>diabetes</keyword>
  <keyword>hormones</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

